|If you have trouble viewing this page, click here to view the newsletter online on our website.|
May 7, 2012
CASE CCC IN THE NEWS
Bainbridge: Tanning Can be a Hard Habit to Break
Turning Plant Virus into Cancer Weapon
Cleveland Clinic Researcher's Breast Cancer Vaccine gets Attention, Financial Boosts
MARK YOUR CALENDARS
Cancer Center Seminar Series: Targeting the Bcl-2 family in cancer therapy: Discovery of selective Mcl-1 inhibitors
Friday, May 11
Please join us May 11 for the next Cancer Center Seminar Series where Dr. Hong-Gang Wang, Professor of Pharmacology at Penn State University, will present Targeting the Bcl-2 family in cancer therapy: Discovery of selective Mcl-1 inhibitors.
The Bcl-2 family of proteins plays a pivotal role in apoptosis by regulating mitochondrial function. High levels of the anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-XL, and Mcl-1) are associated with the pathogenesis of cancer and resistance to therapy. To date, several small-molecule Bcl-2 inhibitors have been synthesized as BH3 mimetics, and three of the molecules (ABT-737/ABT-263, Obatoclax, and Gossypol/AT-101) have entered clinical trials. However, none of these Bcl-2 inhibitors are specific for Mcl-1. At this seminar, Dr. Wang will discuss the need and development of Mcl-1-specific inhibitors for the treatment of cancer as a single agent or in combination therapy.
DOD Peer Reviewed Cancer Research Program
Applications for the Peer Reviewed Cancer Research Program (PRCRP) are being solicited by the Assistant Secretary of Defense for Health Affairs, Defense Health Program. The goal of the PRCRP is to improve quality of life by decreasing the impact of cancer on service members, their families, and the American public. The FY12 PRCRP fosters the next generation of cancer research by providing new and early career investigators opportunities to excel in groundbreaking cutting-edge research for the prevention, detection, and treatment of cancer.
NIH Launches Collaborative Program with Industry and Researchers to Spur Therapeutic Development
The NIH unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients. NIH's new National Center for Advancing Translational Sciences (NCATS) has partnered initially with Pfizer, AstraZeneca, and Eli Lilly and Company which have agreed to make dozens of their compounds available for this initiative's pilot phase.
The initiative, Discovering New Therapeutic Uses for Existing Molecules, will direct researchers' attention to a part of the therapeutic pipeline that traditionally has been difficult for them to access: compounds that already have cleared several key steps in the development process, including safety testing in humans. The President's FY2013 budget proposed $575 million for NCATS, of which approximately $20 million total will be provided to support research grants of up to three years duration for pre-clinical and clinical feasibility studies. These studies will test more than 20 compounds from industry partners for their effectiveness against a variety of diseases and conditions. The companies will provide the researchers with access to the compounds and related data.
The pilot program incorporates innovative template agreements designed to streamline the legal and administrative process for participation by multiple organizations. These template agreements reduce time, cost, and effort, as well as allow greater participation than traditional partnerships.
American Academy of Neurology Annual Meeting
In April, Dr. Lisa Rogers co-directed the Highlights in Neuro-oncology session at the American Academy of Neurology Annual Meeting in New Orleans. Dr. Rogers is the immediate Past President of the Neuro-oncology Section of the American Academy of Neurology.
Cancer Center presentations at the Annual Meeting included:
Race for the Place- Join Our Team!
The Race for the Place, an event that benefits the Gathering Place, will be held Sunday, June 3 at Beachwood Place Mall. The Case CCC has created a CaseCCC Trainees team. Click here to join the team or to show your support by making a donation. Contact Lyn Haselton, Case CCC Training Program Manager, at 216.844.5375 or email@example.com for more information.
NCI Cancer Bulletin
**All events are open to anyone interested in attending
Pathology Research Seminar Series
Cancer Imaging Program Meeting
Cancer Biology Seminar
Molecular Biology and Microbiology Seminar
Hematology and Oncology Division Research Conference
Cancer Pharmacology Training Program Symposium
Immunology Faculty Research in Progress Series
Department of Neurosciences Guest Speaker Series
Sequence-Palooza: What Can Next Gen Sequencing Do For You?
NCRM Lunch and Learn
Taussig Cancer Institute Grand Rounds
Biomedical Engineering Seminar
Cancer Center Seminar Series
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
Case CCC Scientific Series: Imaging Research
Ca-PRI Annual Meeting: Learning from Our Differences
ADDITIONAL UPCOMING SEMINARS & EVENTS
Comparative Effectiveness Research: From All Angles
Cleveland Clinic 2012 Personalized Healthcare Summit
Ninth International Conference of the Society for Integrative Oncology
Biennial Science of Global Prostate Cancer Disparities conference
PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES
AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen for the Cure®
AACR Award for Distinguished Lecture on the Science of Health Disparities, funded by Susan G. Komen for the Cure®
NIH BULLETIN – Notices and Funding Opportunities
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to firstname.lastname@example.org.